美国国立卫生研究院的脉冲环磷酰胺疗法：一个时代的终结？ - Suppr

Suppr

超能文献

The NIH pulse cyclophosphamide regime: the end of an era?

作者信息

Karim Y, D'Cruz D P

出版信息

Lupus. 2004;13(1):1-3. doi: 10.1191/0961203304lu524ed.

DOI:10.1191/0961203304lu524ed

PMID:14870910

Abstract

摘要

相似文献

The NIH pulse cyclophosphamide regime: the end of an era?

Lupus. 2004;13(1):1-3. doi: 10.1191/0961203304lu524ed.

How did cyclophosphamide become the drug of choice for lupus nephritis?

Nephrol Dial Transplant. 2009 Feb;24(2):381-4. doi: 10.1093/ndt/gfn640. Epub 2008 Dec 4.

Treatment of lupus nephritis: art or science?

Intern Med J. 2001 Jul;31(5):264-6. doi: 10.1046/j.1445-5994.2001.00076.x.

Sequential therapies for proliferative lupus nephritis.

N Engl J Med. 2004 Jun 10;350(24):2518-20; author reply 2518-20.

Sequential therapies for proliferative lupus nephritis.

N Engl J Med. 2004 Jun 10;350(24):2518-20; author reply 2518-20. doi: 10.1056/NEJM200406103502416.

Cyclophosphamide in lupus nephritis.

J Rheumatol. 1995 Oct;22(10):1812-5.

Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritis.

N Engl J Med. 2006 Feb 16;354(7):764-5; author reply 764-5. doi: 10.1056/NEJMc053503.

Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritis.

N Engl J Med. 2006 Feb 16;354(7):764-5; author reply 764-5.

Mycophenolate mofetil for lupus nephritis.

N Engl J Med. 2005 Nov 24;353(21):2282-4. doi: 10.1056/NEJMe058256.

Treatment of proliferative lupus nephritis: a changing landscape.

Kidney Int. 2006 Aug;70(4):616-8. doi: 10.1038/sj.ki.5001722.

引用本文的文献

CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice.

Arthritis Res Ther. 2013 Feb 27;15(1):R35. doi: 10.1186/ar4188.

Oral cyclophosphamide is on the verge of extinction as therapy for severe autoimmune diseases (especially lupus): should nephrologists care?

Nephron Clin Pract. 2011;117(1):c8-14. doi: 10.1159/000319641. Epub 2010 Aug 3.

Successful treatment of class V+IV lupus nephritis with multitarget therapy.

J Am Soc Nephrol. 2008 Oct;19(10):2001-10. doi: 10.1681/ASN.2007121272. Epub 2008 Jul 2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

The NIH pulse cyclophosphamide regime: the end of an era?

Lupus. 2004;13(1):1-3. doi: 10.1191/0961203304lu524ed.

How did cyclophosphamide become the drug of choice for lupus nephritis?

Nephrol Dial Transplant. 2009 Feb;24(2):381-4. doi: 10.1093/ndt/gfn640. Epub 2008 Dec 4.

Treatment of lupus nephritis: art or science?

Intern Med J. 2001 Jul;31(5):264-6. doi: 10.1046/j.1445-5994.2001.00076.x.

Sequential therapies for proliferative lupus nephritis.

N Engl J Med. 2004 Jun 10;350(24):2518-20; author reply 2518-20.

Sequential therapies for proliferative lupus nephritis.

N Engl J Med. 2004 Jun 10;350(24):2518-20; author reply 2518-20. doi: 10.1056/NEJM200406103502416.

Cyclophosphamide in lupus nephritis.

J Rheumatol. 1995 Oct;22(10):1812-5.

Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritis.

N Engl J Med. 2006 Feb 16;354(7):764-5; author reply 764-5. doi: 10.1056/NEJMc053503.

Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritis.

N Engl J Med. 2006 Feb 16;354(7):764-5; author reply 764-5.

Mycophenolate mofetil for lupus nephritis.

N Engl J Med. 2005 Nov 24;353(21):2282-4. doi: 10.1056/NEJMe058256.

Treatment of proliferative lupus nephritis: a changing landscape.

Kidney Int. 2006 Aug;70(4):616-8. doi: 10.1038/sj.ki.5001722.

引用本文的文献

CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice.

Arthritis Res Ther. 2013 Feb 27;15(1):R35. doi: 10.1186/ar4188.

Oral cyclophosphamide is on the verge of extinction as therapy for severe autoimmune diseases (especially lupus): should nephrologists care?

Nephron Clin Pract. 2011;117(1):c8-14. doi: 10.1159/000319641. Epub 2010 Aug 3.

Successful treatment of class V+IV lupus nephritis with multitarget therapy.

J Am Soc Nephrol. 2008 Oct;19(10):2001-10. doi: 10.1681/ASN.2007121272. Epub 2008 Jul 2.